151 related articles for article (PubMed ID: 30971332)
41. Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis.
Rai R; Srinivas CR
Indian J Dermatol Venereol Leprol; 2008; 74(3):263-5. PubMed ID: 18583801
[No Abstract] [Full Text] [Related]
42. Toxic epidermal necrolysis in a patient with psoriatic arthritis.
Pace J; Adami JZ; Mallia C; Mizzi A
Adv Exp Med Biol; 1999; 455():557-60. PubMed ID: 10599399
[No Abstract] [Full Text] [Related]
43. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
Zhang S; Tang S; Li S; Pan Y; Ding Y
J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
[No Abstract] [Full Text] [Related]
44. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept.
Gavigan GM; Kanigsberg ND; Ramien ML
J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925
[TBL] [Abstract][Full Text] [Related]
45. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.
Power WJ; Ghoraishi M; Merayo-Lloves J; Neves RA; Foster CS
Ophthalmology; 1995 Nov; 102(11):1669-76. PubMed ID: 9098260
[TBL] [Abstract][Full Text] [Related]
46. [Factors associated with the severity of acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa].
Saka B; Dzidzinyo K; Akakpo S; Téclessou J; Nouhou Diori A; Maneh N; Mahamadou G; Gnassingbé W; Abilogun-Chokki A; Mouhari-Toure A; Boubacar YA; Kombaté K; Balo K; Tchangai-Walla K; Pitché P
Ann Dermatol Venereol; 2018 Apr; 145(4):245-249. PubMed ID: 29487020
[TBL] [Abstract][Full Text] [Related]
47. Cyclosporine in SJS/TEN management: a brief review.
Shokeen D
Cutis; 2016 Mar; 97(3):E17-8. PubMed ID: 27023091
[TBL] [Abstract][Full Text] [Related]
48. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
49. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J
Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729
[TBL] [Abstract][Full Text] [Related]
50. Interventions for toxic epidermal necrolysis.
Majumdar S; Mockenhaupt M; Roujeau J; Townshend A
Cochrane Database Syst Rev; 2002; 2002(4):CD001435. PubMed ID: 12519556
[TBL] [Abstract][Full Text] [Related]
51. Thalidomide in toxic epidermal necrolysis.
Klausner JD; Kaplan G; Haslett PA
Lancet; 1999 Jan; 353(9149):324. PubMed ID: 9929047
[No Abstract] [Full Text] [Related]
52. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
53. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.
Torres-Navarro I; Briz-Redón Á; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):159-171. PubMed ID: 32946187
[TBL] [Abstract][Full Text] [Related]
54. Toxic epidermal necrolysis in oncologic patients.
Gravante G; Delogu D; Esposito G; Montone A
Am J Clin Dermatol; 2006; 7(6):397-8. PubMed ID: 17173477
[No Abstract] [Full Text] [Related]
55. Outcome of Stevens Johnson syndrome and toxic epidermal necrolysis treated with corticosteroids.
Rijal A; Agrawal S
Indian J Dermatol Venereol Leprol; 2009; 75(6):613-4. PubMed ID: 19915248
[No Abstract] [Full Text] [Related]
56. Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept.
Coulombe J; Belzile E; Duhamel A; Rault P; Buteau C; DeBruycker JJ; Bussières JF
J Cutan Med Surg; 2019; 23(5):547-550. PubMed ID: 31478770
[TBL] [Abstract][Full Text] [Related]
57. Toxic epidermal necrolysis treated with cyclosporin.
Hewitt J; Ormerod AD
Clin Exp Dermatol; 1992 Jul; 17(4):264-5. PubMed ID: 1451317
[TBL] [Abstract][Full Text] [Related]
58. Corticosteroids in toxic epidermal necrolysis.
Pasricha JS
Indian J Dermatol Venereol Leprol; 2008; 74(5):493; author reply 493-5. PubMed ID: 19052413
[No Abstract] [Full Text] [Related]
59. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
[TBL] [Abstract][Full Text] [Related]
60. Use of infliximab in toxic epidermal necrolysis: a still opened challenge.
Ganzetti G; Campanati A; Simonetti O; Giuliodori K; Giangiacomi M; Lemme G; Offidani A
G Ital Dermatol Venereol; 2015 Aug; 150(4):467-71. PubMed ID: 25394212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
